This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.

Start Date01 Mar 2018

Sponsor / Collaborator

The First Affiliated Hospital of Zhengzhou University

100 Clinical Results associated with NY-ESO-1 x EGFRvIII

100 Translational Medicine associated with NY-ESO-1 x EGFRvIII

0 Patents (Medical) associated with NY-ESO-1 x EGFRvIII

Literatures (Medical) associated with NY-ESO-1 x EGFRvIII

01 Feb 2017·OncoImmunologyQ2 · MEDICINE

Tumor-infiltrating lymphocytes (TILs) from patients with glioma

Q2 · MEDICINE

ArticleOA

Author: Luo, Xiaohua ; Peredo, Inti Harvey ; Dodoo, Ernest ; Persson, Oscar ; Liu, Zhenjiang ; Rao, Martin Vijayakumar ; Bartek, Jiri ; Rangelova, Elena ; Illies, Christopher ; Poiret, Thomas ; Rane, Lalit ; Meng, Qingda ; Maeurer, Markus ; Robertson, Rebecca Axelsson

Tumor-infiltrating lymphocytes (TILs) may represent a viable source of T cells for the biological treatment of patients with gliomas. Glioma tissue was obtained from 16 patients, tumor cell lines were established, and TILs were expanded in 16/16 cases using a combination of IL-2/IL-15/IL-21. Intracellular cytokine staining (ICS, IL-2, IL-17, TNFα and IFNγ production) as well as a cytotoxicity assay was used to detect TIL reactivity against autologous tumor cells or shared tumor-associated antigens (TAAs; i.e., NY-ESO-1, Survivin or EGFRvIII). TILs were analyzed by flow cytometry, including T-cell receptor (TCR) Vβ family composition, exhaustion/activation and T-cell differentiation markers (CD45RA/CCR7). IL-2/IL-15/IL-21 expanded TILs exhibited a mixture of CD4⁺, CD8⁺, as well as CD3⁺ CD4^-CD8^- T cells with a predominant central memory CD45RA^-CCR7⁺ phenotype. TIL showed low frequencies of T cells testing positive for PD-1, TIM-3 and CTLA-4. LAG3 tested positive in up to 30% of CD8⁺ TIL, with low (1.25%) frequencies in CD4⁺ T cells. TIL cultures exhibited preferential usage of Vβ families and recognition of autologous tumor cells defined by cytokine production and cytotoxicity. IL-2/IL-15/IL-21 expanded TILs represent a viable source for the cellular therapy of patients with gliomas.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis